CN107698660B - 咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用 - Google Patents
咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用 Download PDFInfo
- Publication number
- CN107698660B CN107698660B CN201510642709.6A CN201510642709A CN107698660B CN 107698660 B CN107698660 B CN 107698660B CN 201510642709 A CN201510642709 A CN 201510642709A CN 107698660 B CN107698660 B CN 107698660B
- Authority
- CN
- China
- Prior art keywords
- obzl
- boc
- lys
- asp
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000694 effects Effects 0.000 title description 7
- 238000003786 synthesis reaction Methods 0.000 title description 7
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 50
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 74
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 66
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 31
- 238000010168 coupling process Methods 0.000 claims description 30
- 238000005859 coupling reaction Methods 0.000 claims description 30
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 29
- 230000008878 coupling Effects 0.000 claims description 27
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 11
- 238000007127 saponification reaction Methods 0.000 claims description 9
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 8
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 7
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 claims description 6
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 6
- JNYKZWBVTXFUBQ-LBPRGKRZSA-N benzyl 2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]acetate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C(=O)NCC(=O)OCC1=CC=CC=C1 JNYKZWBVTXFUBQ-LBPRGKRZSA-N 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 229960002885 histidine Drugs 0.000 claims description 6
- 108010039538 alanyl-glycyl-aspartyl-valine Proteins 0.000 claims description 3
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 claims description 3
- ZHDSBMWWRSPRGD-UHFFFAOYSA-N 3,5-bis[(2-methylpropan-2-yl)oxycarbonyl]-4,5,6,7-tetrahydroimidazo[4,5-b]pyridine-6-carboxylic acid Chemical compound C(=O)(OC(C)(C)C)N1C=NC=2CC(C(NC=21)C(=O)OC(C)(C)C)C(=O)O ZHDSBMWWRSPRGD-UHFFFAOYSA-N 0.000 claims 2
- DFXBHSIAIQKXAR-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine-6-carboxylic acid Chemical compound C1C(C(=O)O)CNC2=C1NC=N2 DFXBHSIAIQKXAR-UHFFFAOYSA-N 0.000 claims 1
- FSMGYVPZHCOCES-UHFFFAOYSA-N 7h-imidazo[4,5-b]pyridine-6-carboxylic acid Chemical compound C1C(C(=O)O)=CN=C2N=CN=C21 FSMGYVPZHCOCES-UHFFFAOYSA-N 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000001117 sulphuric acid Substances 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 57
- 150000001875 compounds Chemical class 0.000 description 55
- 239000007787 solid Substances 0.000 description 48
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 44
- 238000000034 method Methods 0.000 description 33
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- SOHLZANWVLCPHK-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-phenylmethoxybutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(=O)OCC1=CC=CC=C1 SOHLZANWVLCPHK-LBPRGKRZSA-N 0.000 description 24
- YCFJXOFFQLPCHD-UHFFFAOYSA-N (S)-Spinacine Chemical compound C1NC(C(=O)O)CC2=C1NC=N2 YCFJXOFFQLPCHD-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- CCGHCCTXMYYHQC-UHFFFAOYSA-N 3,5-bis[(2-methylpropan-2-yl)oxycarbonyl]-6,7-dihydro-4h-imidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC2=C1N=CN2C(=O)OC(C)(C)C CCGHCCTXMYYHQC-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229940124280 l-arginine Drugs 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- FJBAOZHBRMLMCP-UHFFFAOYSA-N 2-(benzylazaniumyl)-3-methylbutanoate Chemical compound CC(C)C(C(O)=O)NCC1=CC=CC=C1 FJBAOZHBRMLMCP-UHFFFAOYSA-N 0.000 description 3
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- DVCSNHXRZUVYAM-BQBZGAKWSA-N leu-asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 1
- PIVJVCRQCUYKNZ-HNNXBMFYSA-N (2s)-2-(benzylazaniumyl)-3-phenylpropanoate Chemical compound C([C@@H](C(=O)O)NCC=1C=CC=CC=1)C1=CC=CC=C1 PIVJVCRQCUYKNZ-HNNXBMFYSA-N 0.000 description 1
- MDNRBNZIOBQHHK-KWBADKCTSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N MDNRBNZIOBQHHK-KWBADKCTSA-N 0.000 description 1
- ARNGIGOPGOEJCH-KKUMJFAQSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ARNGIGOPGOEJCH-KKUMJFAQSA-N 0.000 description 1
- KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 description 1
- 108010091818 arginyl-glycyl-aspartyl-valine Proteins 0.000 description 1
- IIDNACBMUWTYIV-VIFPVBQESA-N benzyl (2s)-2-amino-3-hydroxypropanoate Chemical compound OC[C@H](N)C(=O)OCC1=CC=CC=C1 IIDNACBMUWTYIV-VIFPVBQESA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了通式I的4,5,6,7‑四氢‑3H‑咪唑并[4,5‑c]吡啶‑6‑甲酰‑Lys(Lys)‑AA1‑AA2‑Asp‑AA3,公开了它们的制备方法,公开了它们的抗血栓活性以及抗炎活性,因而本发明公开了它们在制备抗血栓和抗炎药物中的应用。
Description
技术领域
本发明涉及4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3，涉及它们的制备方法,涉及它们的抗血栓活性以及抗炎活性,因而本发明涉及它们在制备抗血栓和抗炎药物中的应用。本发明属于生物医药领域。
背景技术
冠心病、脑卒中以及脉管炎等是非常常见的心脑血管疾病。随着人们生活水平的不断提高，心脑血管疾病的发病人数逐年递增。心脑血管疾病危险因素流行，我国心脑血管疾病的患病率持续上升。据资料统计，每5个成年人中就有1个心血管病患者。血栓形成是心脑血管疾病的重要病因。预防血栓形成仍然依赖药物治疗。临床常用的血栓类药物有阿司匹林、氯吡格雷和华法林等。它们都存在一些副作用，如出血和胃肠道刺激等。因此，寻找疗效好、副作用小的抗血栓药物是很有意义的。
近年来，发明人发现含有咪唑并四氢吡啶杂环的化合物是抗血栓活性的优秀结构。发明人曾经公开下式的4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-AA(式中AA为氨基酸残基)在10nmol/kgd的口服剂量下具有确切的抗血栓活性。不过，发明人对这个剂量并不满意。
经过3年实验探索，发明人发现用寡肽代替上式的AA不仅可以降低口服剂量，还可以获得额外的抗炎作用。按照这些发现，发明人提出了本发明。
发明内容
本发明的第一个内容是提供通式I的4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3(式中AA1为Ala,AA2为Gly和AA3为Val时AA1-AA2-Asp-AA3为Ala-Gly-Asp-Val；式中AA1不存在AA2为Leu和AA3为Val时AA1-AA2-Asp-AA3为Leu-Asp-Val；式中AA1为Arg,AA2为Gly和AA3为Val时AA1-AA2-Asp-AA3为Arg-Gly-Asp-Val；式中AA1为Arg,AA2为Gly和AA3为Phe时AA1-AA2-Asp-AA3为Arg-Gly-Asp-Phe；式中AA1为Arg,AA2为Gly和AA3为Ser时AA1-AA2-Asp-AA3为Arg-Gly-Asp-Ser),公开了它们的制备方法,公开了它们的抗血栓活性以及抗炎活性,因而本发明公开了它们在制备抗血栓和抗炎药物中的应用。
本发明的第二个内容是提供通式I的4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3的合成方法，该方法包括：
(1)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Ala-Gly-Asp-Val的合成：
(1.1)L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(1.2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(1.3)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与Lys(Boc)-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl；
(1.4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)；
(1.5)Boc-Ala与甘氨酸苄酯偶联得到Boc-Ala-Gly-OBzl；
(1.6)Boc-Ala-Gly-OBzl在2N NaOH溶液中皂化成Boc-Ala-Gly；
(1.7)Boc-Asp(OBzl)与缬氨酸苄酯偶联得到Boc-Asp(OBzl)-Val-OBzl；
(1.8)Boc-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Asp(OBzl)-Val-OBzl；
(1.9)Boc-Ala-Gly与L-Asp(OBzl)-Val-OBzl偶联得到Boc-Ala-Gly-Asp(OBzl)-Val-OBzl；
(1.10)Boc-Ala-Gly-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Ala-Gly-Asp(OBzl)-Val-OBzl；
(1.11)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)与L-Ala-Gly-Asp(OBzl)-Val-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Ala-Gly-Asp(OBzl)-Val-OBzl；
(1.12)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Ala-Gly-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Ala-Gly-Asp(OBzl)-Val-OBzl；
(1.13)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Ala-Gly-Asp(OBzl)-Val-OBzl与Boc-Lys(Z)偶联得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Ala-Gly-Asp(OBzl)-Val-OBzl；
(1.14)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Ala-Gly-Asp(OBzl)-Val
-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Ala-Gly-Asp-Val。
(2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Leu-Asp-Val的合成：
(2.1)L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(2.2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(2.3)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与Lys(Boc)-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl；
(2.4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)；
(2.5)Boc-Asp(OBzl)与缬氨酸苄酯偶联得到Boc-Asp(OBzl)-Val-OBzl；
(2.6)Boc-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Asp(OBzl)-Val-OBzl；
(2.7)Boc-Leu与L-Asp(OBzl)-Val-OBzl偶联得到Boc-Leu-Asp(OBzl)-Val-OBzl；
(2.8)Boc-Leu-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Leu-Asp(OBzl)-Val-OBzl；
(2.9)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)与L-Leu-Asp(OBzl)-Val-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Leu-Asp(OBzl)-Val-OBzl；
(2.10)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Leu-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Leu-Asp(OBzl)-Val-OBzl；
(2.11)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Ala-Gly-Asp(OBzl)-Val-OBzl与Boc-Lys(Z)偶联得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Leu-Asp(OBzl)-Val-OBzl；
(2.12)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Leu-Asp(OBzl)-Val-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Leu-Asp-Val。
(3)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg(NO2)-Gly-Asp-Val的合成：
(3.1)L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(3.2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(3.3)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与Lys(Boc)-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl；
(3.4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)；
(3.5)Boc-Arg(NO2)与甘氨酸苄酯偶联得到Boc-Arg(NO2)-Gly-OBzl；
(3.6)Boc-Arg(NO2)-Gly-OBzl在2N NaOH溶液中皂化成Boc-Arg(NO2)-Gly；
(3.7)Boc-Asp(OBzl)与缬氨酸苄酯偶联得到Boc-Asp(OBzl)-Val-OBzl；
(3.8)Boc-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Asp(OBzl)-Val-OBzl；
(3.9)Boc-Arg(NO2)-Gly与L-Asp(OBzl)-Val-OBzl偶联得到Boc-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl；
(3.10)Boc-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl；
(3.11)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)与L-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl；
(3.12)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl；
(3.13)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl与Boc-Lys(Z)偶联得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-
Gly-Asp(OBzl)-Val-OBzl；
(3.14)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-
Val-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Val。
(4)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg(NO2)-Gly-Asp-Phe的合成：
(4.1)L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(4.2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(4.3)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与Lys(Boc)-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl；
(4.4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)；
(4.5)Boc-Arg(NO2)与甘氨酸苄酯偶联得到Boc-Arg(NO2)-Gly-OBzl；
(4.6)Boc-Arg(NO2)-Gly-OBzl在2N NaOH溶液中皂化成Boc-Arg(NO2)-Gly；
(4.7)Boc-Asp(OBzl)与苯丙氨酸苄酯偶联得到Boc-Asp(OBzl)-Phe-OBzl；
(4.8)Boc-Asp(OBzl)-Phe-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Asp(OBzl)-Phe-OBzl；
(4.9)Boc-Arg(NO2)-Gly与L-Asp(OBzl)-Phe-OBzl偶联得到Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl；
(4.10)Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl；
(4.11)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)与L-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl；
(4.12)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl在4N氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl；
(4.13)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl与Boc-Lys(Z)偶联得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-
Gly-Asp(OBzl)-Phe-OBzl；
(4.14)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-
Phe-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Phe。
(5)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg(NO2)-Gly-Asp-Ser的合成：
(5.1)L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(5.2)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸；
(5.3)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与Lys(Boc)-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl；
(5.4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)；
(5.5)Boc-Arg(NO2)与甘氨酸苄酯偶联得到Boc-Arg(NO2)-Gly-OBzl；
(5.6)Boc-Arg(NO2)-Gly-OBzl在2N NaOH溶液中皂化成Boc-Arg(NO2)-Gly；
(5.7)Boc-Asp(OBzl)与丝氨酸苄酯偶联得到Boc-Asp(OBzl)-Ser-OBzl；
(5.8)Boc-Asp(OBzl)-Ser-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Asp(OBzl)-Ser-OBzl；
(5.9)Boc-Arg(NO2)-Gly与L-Asp(OBzl)-Ser-OBzl偶联得到Boc-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl；
(5.10)Boc-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl；
(5.11)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)与L-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl；
(5.12)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl在4N氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl；
(5.13)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl与Boc-Lys(Z)偶联得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-
Gly-Asp(OBzl)-Ser-OBzl；
(5.14)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Ser。
本发明的第三个内容是评价4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-peptide对SD大鼠的抗血栓作用。
本发明的第六个内容是评价4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Ala-Gly-Asp-Val和4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Ser对ICR小鼠炎症的抑制作用。
附图说明
图1.4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3，化合物为8e)的合成路线.i)HCHO,H2SO4,65℃；ii)(Boc)2O,4N NaOH；iii)二环己基碳二亚胺(DCC),1-羟基苯并三唑(HOBt),N-甲基吗啉(NMM),四氢呋喃(THF)；iv)2N NaOH,CH3OH；v)4N HCl/EA；vi)TFA/TFMSA。
具体实施方式
为了进一步阐述本发明，下面给出一系列实施例。这些实施例完全是例证性的，它们仅用来对本发明进行具体描述，不应当理解为对本发明的限制。
实施例1制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸(1)
冰浴和搅拌下向5g(32.3mmol)L-His与18mL水的溶液中缓慢滴加0.8mL H2SO4，使完全溶解。向该溶液中加6mL 40％甲醛水溶液。撤去冰浴，60℃反应8h，TLC(乙酸乙酯：水：冰醋酸＝4:1:1)监测原料点消失。将反应液冷却至室温，冰浴下用浓氨水调节pH至6，有大量无色固体析出。过滤。滤渣用水和丙酮洗涤，得4.52g(84％)标题化合物。ESI-MS(m/e):168[M+H]+。
实施例2制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸(2)
冰浴和搅拌下向5g(29.9mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸与40mL水的溶液中加40mL 1,4-二氧六环溶解的14.3g(65.7mmol)(Boc)2O，用4N NaOH溶液调节pH至8-9，室温反应24h，TLC(二氯甲烷：甲醇＝15:1)监测原料点消失。反应液用饱和KHSO4溶液调节pH至7，减压蒸出1,4-二氧六环后，用饱和KHSO4溶液调节pH至2。用乙酸乙酯萃取三次，酯层用饱和NaCl洗三次。用无水硫酸钠干燥30min，过滤。将滤液减压蒸干。加少量乙酸乙酯将其刚好溶解，静置。有固体析出，过滤。得1.2g(11％)标题化合物，为无色固体。ESI-MS(m/e):368[M+H]+。
实施例3制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl(3)
冰浴下，用20mL干燥的四氢呋喃(THF)将367mg(1mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-羧酸溶解。加入142mg(1.05mmol)HOBt以及258mg(1.25mmol)DCC，搅拌活化30min。用10mL干燥的THF将558mg(1.1mmol)Tos·Lys(Boc)-OBzl溶解，用NMM调节pH至8，将该溶液滴加至反应液中，最后用NMM调节反应液pH至8。室温反应5h，TLC(石油醚：丙酮＝3:1)显示原料消失。过滤除去二环己基脲(DCU)，减压蒸干反应液，剩余物用乙酸乙酯溶解后，依次用饱和NaHCO3溶液、饱和NaCl溶液、5％KHSO4溶液、饱和NaCl溶液、饱和NaHCO3溶液、饱和NaCl溶液各洗三次。乙酸乙酯层用无水Na2SO4干燥30min，过滤，滤液减压蒸干。所得黄色油状物经硅胶柱层析纯化(石油醚/丙酮为洗脱剂)，得248mg(36％)标题化合物，为无色固体。ESI-MS(m/e):686[M+H]+。
实施例4制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)(4)
冰浴下，用20mL甲醇将685mg(1mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-OBzl溶解，用2N NaOH溶液调节pH至12，冰浴反应5h，TLC(石油醚：丙酮＝3:1)显示原料点消失。用饱和KHSO4溶液调节pH至7。减压蒸出甲醇，用饱和KHSO4溶液调节pH至2，用乙酸乙酯萃取3次，乙酸乙酯层用饱和NaCl溶液洗三次，用无水Na2SO4干燥30min，过滤，旋干滤液。得584mg(98％)标题化合物，为无色固体。ESI-MS(m/e):596[M+H]+。
实施例5制备Boc-Ala-Gly-OBzl
冰浴和搅拌下用30mL干燥的THF将945mg(5mmol)Boc-Ala溶解。依次加入708mg(5.25mmol)HOBt及1.291g(6.25mmol)DCC，活化30min。用干燥的THF将2.022g(6mmol)Tos·Gly-OBzl溶解后，用NMM调pH至8，然后将该溶液滴加至反应液中，最后用NMM调反应液pH至8。室温反应12小时，TLC(二氯甲烷：甲醇＝25:1)显示反应完毕后，将反应液减压蒸干，剩余油状物用乙酸乙酯溶解，过滤除去DCU，滤液依次用饱和NaHCO3溶液、饱和NaCl溶液、饱和KHSO4溶液、饱和NaCl溶液、饱和NaHCO3溶液、饱和NaCl溶液各洗三遍，乙酸乙酯层用无水Na2SO4干燥30min，过滤。滤液减压浓缩至干，将得到的黄色油状物经无水乙醚磨洗，得到1.471g(88％)标题化合物，为无色固体。ESI-MS(m/e):337[M+H]+。
实施例6制备Boc-Ala-Gly
冰浴下，用40mL甲醇将1.680g(5mmol)Boc-Ala-Gly-OBzl溶解，用2N NaOH溶液调节pH至12，冰浴反应5h，TLC(二氯甲烷：甲醇＝25:1)显示原料点消失。用饱和KHSO4溶液调节pH至7。减压蒸出甲醇，用饱和KHSO4溶液调节pH至2，用乙酸乙酯萃取三次，乙酸乙酯层用饱和NaCl溶液洗三次，用无水Na2SO4干燥30min，过滤。滤液减压浓缩至干。得1.11g(90％)标题化合物，为无色固体。ESI-MS(m/e):245[M+H]-。
实施例7制备Boc-Asp(OBzl)-Val-OBzl
按照实施例5的方法从1.615g(5mmol)Boc-Asp(OBzl)和2.369g(6mmol)Tos·Val-OBzl得到2.081g(81％)标题化合物，为无色固体。ESI-MS(m/e):513[M+H]+。
实施例8制备HCl·Asp(OBzl)-Val-OBzl
冰浴和搅拌下，用少量干燥的乙酸乙酯将1.024g(2mmol)Boc-Asp(OBzl)-Val-OBzl溶解。向该溶液中加20ml 4N氯化氢的乙酸乙酯溶液，冰浴下反应6小时，TLC(石油醚：丙酮＝3:1)显示反应完毕后，将反应液减压浓缩至干。向残余物中加干燥的乙酸乙酯，减压浓缩至干，重复两次。再向残余物中加无水乙醚，减压浓缩至干，重复三次。得0.751g(91％)标题化合物，为淡黄色固体。ESI-MS(m/e):413[M+H]+。
实施例9制备Boc-Ala-Gly-Asp(OBzl)-Val-OBzl
按照实施例5的方法从1.230g(5mmol)Boc-Ala-Gly和2.700g(6mmol)HCl·Asp(OBzl)-Val-OBzl得到2.650g(83％)标题化合物，为无色固体。ESI-MS(m/e):641[M+H]+。
实施例10制备HCl·Ala-Gly-Asp(OBzl)-Val-OBzl
按照实施例8的方法从1.280g(2mmol)Boc-Ala-Gly-Asp(OBzl)-Val-OBzl得到0.969g(90％)标题化合物，为淡黄色固体。ESI-MS(m/e):541[M+H]+。
实施例11制备Boc-Leu-Asp(OBzl)-Val-OBzl
按照实施例5的方法从1.155g(5mmol)Boc-Leu和2.700g(6mmol)HCl·Asp(OBzl)-Val-OBzl得到2.456g(79％)标题化合物，为无色固体。ESI-MS(m/e):626[M+H]+。
实施例12制备HCl·Leu-Asp(OBzl)-Val-OBzl
按照实施例8的方法从1.250g(2mmol)Boc-Leu-Asp(OBzl)-Val-OBzl得到0.950g(91％)标题化合物，为淡黄色固体。ESI-MS(m/e):526[M+H]+。
实施例13制备Boc-Arg(NO2)-Gly-OBzl
按照实施例5的方法从1.595g(5mmol)Boc-Arg(NO2)和2.022g(6mmol)Tos·Gly-OBzl得到1.866g(80％)标题化合物，为无色固体。ESI-MS(m/e):467[M+H]+。
实施例14制备Boc-Arg(NO2)-Gly
按照实施例6的方法从1.680g(5mmol)Boc-Arg(NO2)-Gly-OBzl得1.737g(92％)标题化合物，为无色固体。ESI-MS(m/e):375[M+H]-。
实施例15制备Boc-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl
按照实施例5的方法从1.880g(5mmol)Boc-Arg(NO2)-Gly和2.700g(6mmol)HCl·Asp(OBzl)-Val-OBzl得到2.903g(75％)标题化合物，为无色固体。ESI-MS(m/e):771[M+H]+。
实施例16制备HCl·Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl
按照实施例8的方法从1.540g(2mmol)Boc-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl得到1.187g(89％)标题化合物，为淡黄色固体。ESI-MS(m/e):671[M+H]+。
实施例17制备Boc-Asp(OBzl)-Phe-OBzl
按照实施例5的方法从1.615g(5mmol)Boc-Asp(OBzl)和2.669g(6mmol)Tos·Phe-OBzl得2.500g(89％)标题化合物，为无色固体。ESI-MS(m/e):561[M+H]+。
实施例18制备HCl·Asp(OBzl)-Phe-OBzl
按照实施例8的方法从1.120g(2mmol)Boc-Asp(OBzl)-Phe-OBzl得0.802g(87％)标题化合物，为淡黄色固体。ESI-MS(m/e):461[M+H]+。
实施例19制备Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl
按照实施例5的方法从1.880g(5mmol)Boc-Arg(NO2)-Gly和3.014g(6mmol)HCl·Asp(OBzl)-Phe-OBzl得3.251g(80％)标题化合物，为无色固体。ESI-MS(m/e):819[M+H]+。
实施例20制备HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl
按照实施例8的方法从1.636g(2mmol)Boc-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得1.301g(91％)标题化合物，为淡黄色固体。ESI-MS(m/e):719[M+H]+。
实施例21制备Boc-Asp(OBzl)-Ser-OBzl
按照实施例5的方法从1.615g(5mmol)Boc-Asp(OBzl)和2.294g(6mmol)Tos·Ser-OBzl得1.940g(78％)标题化合物，为无色固体。ESI-MS(m/e):501[M+H]+。
实施例22制备HCl·Asp(OBzl)-Ser-OBzl
按照实施例8的方法从1g(2mmol)Boc-Asp(OBzl)-Ser-OBzl得1.669g(93％)标题化合物，为淡黄色固体。ESI-MS(m/e):401[M+H]+。
实施例23制备Boc-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl
按照实施例5的方法从1.880g(5mmol)Boc-Arg(NO2)-Gly和2.621g(6mmol)HCl·Asp(OBzl)-Ser-OBzl得2.884g(76％)标题化合物，为无色固体。ESI-MS(m/e):759[M+H]+。
实施例24制备HCl·Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl
按照实施例8的方法从1.636g(2mmol)Boc-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl得1.196g(91％)标题化合物，为淡黄色固体。ESI-MS(m/e):659[M+H]+。
实施例25制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Ala-Gly-Asp(OBzl)-Val-OBzl(5a)
按照实施例5的方法从893mg(1.5mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)和862mg HCl·Ala-Gly-Asp(OBzl)-Val-OBzl得1.22g(73％)标题化合物，为无色固体。ESI-MS(m/e):1118[M+H]+。
实施例26制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Leu-Asp(OBzl)-Val-OBzl(5b)
按照实施例5的方法从952mg(1.6mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)和906mg HCl·Leu-Asp(OBzl)-Val-OBzl得1.15g(65％)标题化合物，为无色固体。ESI-MS(m/e):1103[M+H]+。
实施例27制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl(5c)
按照实施例5的方法从906mg(1.52mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)和1.06g HCl·Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl得1.39g(73％)标题化合物，为无色固体。ESI-MS(m/e):1248[M+H]+。
实施例28制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl(5d)
按照实施例5的方法从595mg(1mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)和900mg HCl·Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得794mg(61％)标题化合物，为无色固体。ESI-MS(m/e):1296[M+H]+。
实施例29制备3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl(5e)
按照实施例5的方法从595mg(1.6mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)和834mg HCl·Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl得721mg(58％)标题化合物，为无色固体。ESI-MS(m/e):1236[M+H]+。
实施例30制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Ala-Gly-Asp(OBzl)-Val-OBzl(6a)
按照实施例8的方法从100mg(0.09mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Ala-Gly-Asp(OBzl)-Val-OBzl得65.2mg(89％)标题化合物，为无色固体。ESI-MS(m/e):818[M+H]+。
实施例31制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Leu-Asp(OBzl)-Val-OBzl(6b)
按照实施例8的方法从100mg(0.09mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Leu-Asp(OBzl)-Val-OBzl得65.7mg(90％)标题化合物，为无色固体。ESI-MS(m/e):803[M+H]+。
实施例32制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl(6c)
按照实施例8的方法从100mg(0.08mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl得122.0mg(93％)标题化合物，为无色固体。ESI-MS(m/e):948[M+H]+。
实施例33制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl(6d)
按照实施例8的方法从100mg(0.08mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得70.6mg(92％)标题化合物，为无色固体。ESI-MS(m/e):996[M+H]+。
实施例34制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl(6e)
按照实施例8的方法从100mg(0.08mmol)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Boc)-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl得68.6mg(91％)标题化合物，为无色固体。ESI-MS(m/e):936[M+H]+。
实施例35制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Ala-Gly-Asp(OBzl)-Val-OBzl(7a)
按照实施例5的方法从380mg(1mmol)Boc-Lys(Z)和898mg(1.1mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Ala-Gly-Asp(OBzl)-Val-OBzl得630mg(53％)标题化合物，为无色固体。ESI-MS(m/e):1180[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝11.730(s,1H),8.249-8.147(m,4H),7.945(d,J＝8.1Hz,1H),7.767(t,J＝8.1Hz,1H),7.425(s,1H),7.384-7.262(m,15H),6.774(d,J＝8.1Hz,1H),5.154-5.020(m,4H),4.992(s,2H),4.767(m,1H),4.329-4.246(m,2H),4.175(dd,J＝7.8Hz,6.3Hz,1H),3.810(m,1H),3.706(d,J＝3.3Hz,4H),3.449(dd,J＝8.7Hz,4.8Hz,1H),3.034-2.889(m,4H),2.792-2.550(m,4H),2.055(m,1H),1.682-1.055(m,24H),0.841(d,J＝6.6Hz,6H)。
实施例36制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Leu-Asp(OBzl)-Val-OBzl(7b)
按照实施例5的方法从103mg(0.27mmol)Boc-Lys(Z)和217mg(0.30mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Leu-Asp(OBzl)-Val-OBzl得198mg(63％)标题化合物，为无色固体。ESI-MS(m/e):1165[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝7.975(t,1H),7.731(t,1H),7.426-7.216(m,14H),5.159-5.057(m,4H),4.999(s,1H),4.701(dd,J＝13.8Hz,8.1Hz,1H),4.341-4.246(m,1H),4.202(dd,J＝7.8Hz,6.0Hz,1H),3.920-3.653(m,3H),3.510-3.421(m,2H),3.055-2.953(m,4H),2.817-2.714(m,1H),2.664-2.581(m,1H),2.151-2.002(m,1H),1.631-1.238(m,32H),0.870-0.821(m,12H)。
实施例37制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl(7c)
按照实施例5的方法从91mg(0.24mmol)Boc-Lys(Z)和234mg(0.26mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl得168mg(54％)标题化合物，为无色固体。ESI-MS(m/e):1310[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝8.313(d,J＝7.8Hz,1H),8.233-8.153(m,3H),7.809(s,1H),7.501(s,1H),7.385-7.244(m,15H),5.152-5.023(m,4H),4.990(s,2H),4.768(dd,J＝13.8Hz,8.4Hz,1H),4.297-4.221(m,2H),4.171(dd,J＝7.8Hz,6.3Hz,1H),3.807(s,2H),3.722(d,J＝5.1Hz,2H),3.241(s,2H),2.956(m,4H),2.776-2.705(m,1H),2.622-2.543(m,1H),2.060(m,1H),1.688-1.109(m,31H),0.840(d,J＝5.7Hz,6H)。
实施例38制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl(7d)
按照实施例5的方法从88mg(0.23mmol)Boc-Lys(Z)和230mg(0.25mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得168mg(45％)标题化合物，为无色固体。ESI-MS(m/e):1358[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝9.723(s,1H),8.624(s,1H),8.454(d,J＝7.5Hz,1H),8.265(d,J＝7.8Hz,1H),8.148(d,J＝4.8Hz,1H),7.792(s,1H),7.363-7.169(m,20H),7.023(s,1H),6.751(d,J＝8.1Hz,1H),5.112-4.992(m,6H),4.724(dd,J＝13.5Hz,8.1Hz,1H),4.492(dd,J＝7.8Hz,J＝14.7Hz,1H),4.333-4.306(m,2H),4.223-4.041(m,2H),3.816(dd,J＝13.8Hz,9.0Hz,1H),3.721(d,J＝5.1Hz,1H),3.155(s,3H),3.073-2.921(m,6H),2.837-2.794(m,1H),2.746-2.532(m,2H),1.700-1.236(m,27H)。
实施例39制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl(7e)
按照实施例5的方法从92mg(0.24mmol)Boc-Lys(Z)和227mg(0.26mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl得126mg(62％)标题化合物，为无色固体。ESI-MS(m/e):1298[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝8.245(t,1H),8.161(d,J＝7.5Hz,1H),8.005(d,J＝7.2Hz,1H),7.781(t,J＝5.1Hz,1H),7.428-7.245(m,15H),6.781(d,J＝8.1Hz,1H),5.202-5.062(m,4H),4.991(s,2H),4.790(dd,J＝13.2Hz,8.1Hz,1H),4.368(dd,J＝4.5Hz,J＝12Hz,1H),4.282(m,1H),3.816-3.660(m,6H),3.550(m,1H),3.148(s,2H),3.051-2.890(m,4H),2.806-2.543(m,4H),1.699-1.233(m,28H),0.933-0.829(m,6H)。
实施例40制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Ala-Gly-Asp-Val(8a)
冰浴和搅拌下，向60mg(0.05mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Ala-Gly-Asp(OBzl)-Val-OBzl中滴加1.8mL三氟乙酸，使其完全溶解。滴加0.6mL三氟甲磺酸，溶液变为橘黄色。加干燥管冰浴反应25min，加入大量乙醚，有无色固体析出。离心后倾去上清液，固体再加乙醚，如此反复磨洗三次。用少量水将所得固体溶解，用稀释的氨水调节pH至8，再用稀释的冰醋酸调节pH至7。经Sephadex G10柱子除盐，冷冻干燥，得21mg(54％)标题化合物，为无色固体。Mp:170.9-171.8℃.
(c＝0.11,CH3OH).IR(KBr):3259,3049,2931,2871,1647,1518,1455,1387,1231,1012,995,955,925,651,626,605；ESI-MS(m/e):766[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝8.756(s,1H),8.479(s,1H),8.384(d,J＝6.9Hz,1H),8.094-7.901(m,3H),7.433(s,1H),4.624-4.577(m,1H),4.341-4.277(m,3H),3.921(q,J＝4.8Hz,1H),3.817-3.802(m,1H),3.767-3.612(m,6H),3.580(s,1H),3.455(dd,J＝8.7Hz,4.8Hz,1H),3.169-3.036(m,2H),2.847-2.572(m,5H),2.447-2.261(m,1H),2.033(m,1H),1.686-1.205(m,15H),0.796(d,J＝6.6Hz,1H)。
实施例41制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Leu-Asp-Val(8b)
按照实施例40的方法从58mg(0.05mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Leu-Asp(OBzl)-Val-OBzl得18.7mg(51％)标题化合物，为无色固体。Mp 203.0-203.8℃.[α]20 D＝-63.543(c＝0.11,CH3OH).IR(KBr):3255,2961,2924,1645,1532,1393,1251,1200,1178,1132,1016,956,834,799,720,652,627,570；ESI-MS(m/e):751[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝8.394-8.272(m,1H),8.103(m,1H),7.443(s,1H),4.506(q,1H),4.347-4.330(m,3H),3.896(m,2H),6.773-3.450(m,6H),3.079(s,1H),2.473-2.583(m,4H),2.498-2.385(m,1H),2.012(m,1H),1.551-1.322(m,17H),0.878-0.791(m,12H)。
实施例42制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Val(8c)
按照实施例40的方法从52mg(0.04mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Val-OBzl得18.1mg(57％)标题化合物，为无色固体。Mp 202.7-203.9℃.
(c＝0.12,CH3OH).IR(KBr):3197,3058,2936,1660,1650,1533,1472,1395,1251,1201,1179,1132,1033,955,918,834,799,720,650,627,602；ESI-MS(m/e):851[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝10.359(s,1H),9.263(d,J＝8.1Hz,1H),8.760(s,1H),8.601(d,J＝7.8Hz,1H),8.256(d,J＝7.8Hz,1H),7.997(s,1H),7.417(s,1H),6.969(d,J＝8.1Hz,1H),4.330-4.258(m,3H),3.952(dd,J＝16.8Hz,5.7Hz,1H),3.780(q,1H),3.685(d,J＝7.5Hz,1H),3.433(dd,J＝12Hz,4.8Hz,1H),3.191-3.107(m,2H),3.058-3.021(m,2H),2.898(s,1H),2.730-2.701(m,3H),2.590-2.538(m,2H),2.244-2.174(m,1H),2.023-1.942(m,1H),1.712-1.290(m,22H),0.755(d,J＝5.7Hz,6H)。
实施例43制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Phe(8d)
按照实施例40的方法从54mg(0.04mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Phe-OBzl得19.7mg(55％)标题化合物，为无色固体。Mp 178.1-179.2℃.
(c＝0.12,CH3OH).IR(KBr):3202,3047,2893,1890,1651,1470,1436,1177,840,801,724,601,569；ESI-MS(m/e):899[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝10.130(s,1H),9.056(d,J＝7.2Hz,1H),8.581(s,1H),8.267(d,J＝7.2Hz,1H),8.192(s,1H),8.025(d,J＝7.8Hz,1H),7.434(s,1H),7.150(m,7H),4.349(m,1H),4.259(m,2H),4.028(dd,J＝12.3Hz,5.4Hz,1H),3.708(s,1H),3.454(m,1H),3.130(m,1H),2.978(m,1H),2.715(m,4H),2.270(m,1H),1.976(m,1H),1.653-1.188(m,14H)。
实施例44制备4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys(Lys)-Arg-Gly-Asp-Ser(8e)
按照实施例40的方法从62mg(0.05mmol)4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-Lys[Boc-Lys(Z)]-Arg(NO2)-Gly-Asp(OBzl)-Ser-OBzl得18.9mg(47％)标题化合物，为无色固体。Mp 155.2-156.7℃.
(c＝0.14,CH3OH).IR(KBr):3066,2938,1660,1533,1434,1246,1183,1134,1030,927,838,799,761,722,639,601,577；ESI-MS(m/e):839[M+H]+.1H-NMR(300Hz,DMSO-d6):δ/ppm＝10.120(s,1H),8.758(s,1H),8.646(d,J＝8.4Hz,1H),8.351(d,J＝7.2Hz,1H),8.232(d,J＝6.3Hz,1H),7.963(d,J＝8.1Hz,1H),7.451(s,1H),7.133(d,J＝6.6Hz,1H),7.043(s,1H),4.332(m,2H),4.238(s,1H),4.007(m,2H),3.454(m,1H),3.854(dd,J＝12.0Hz,5.4Hz,1H),3.516(m,4H),3.468(dd,J＝9.3Hz,5.1Hz,1H),3.219(m,4H),2.990(m,2H),2.747(m,4H),2.595(m,2H),2.264(m,1H),2.015(m,1H),1.466(m,17H)。
实验例1评价化合物8a-e的抗血栓活性:
将雄性SD大鼠(200±20g)，随机分组，每组12只，饲养1天，停止喂食过夜。灌胃给予化合物8a-e的生理盐水溶液(剂量为1nmol/kg)或阿司匹林的生理盐水溶液(剂量为167μmol/kg)或生理盐水(剂量为10mL/kg)30min之后，大鼠用20％乌来糖的生理盐水溶液麻醉，之后手术。分离大鼠的右颈动脉和左颈静脉，将准确称重的丝线置于旁路插管，管的一端插入左静脉，另一端管插入右侧动脉并注射0.2mL肝素钠抗凝。使得血流从右侧动脉流经旁路插管进入左侧静脉，15min之后取出附有血栓的丝线称量，计算血液循环前后丝线的重量，得到的血栓重以均值±SD mg表示并代表抗血栓活性，作t检验。数据列入表1。结果表明口服1nmol/kg化合物8a-e能有效地抑制血栓形成。获得了意想不到的技术效果。
表1 1nmol/kg化合物8a-e的抗血栓活性
n＝12；a)与生理盐水比p<0.01；b)与生理盐水比p<0.05；c)与生理盐水比p<0.01,与阿司匹林比p>0.05。
实验例2评价化合物8a和8c的抗炎活性:
1)实验方法
20±2g ICR雄性小鼠随机分为空白对照组、阳性用药组及给药组，小鼠使用前静息1天，操作间保持室内温度22℃，每组小鼠12只。一次给药30分钟后往小白鼠的左耳外廓涂二甲苯(0.03mL)，2小时后将小白鼠颈椎脱臼处死。将小鼠的左，右耳剪下，用直径7mm的打孔器在两耳的相同位置，取圆形耳片，分别称重，求出两圆耳片的重量差作为肿胀度。肿胀度＝左耳原片重量-右耳原片重量。
2)给药方法和剂量
给药方式为灌胃给药。空白对照：生理盐水，给药剂量为0.2mL/20g；阳性对照：阿司匹林，给药剂量为1.11mmol/kg；本发明化合物的给药剂量为1nmol/kg。
3)统计方法
本实验数据统计均采用t检验和方差分析，肿胀度以
表示。
4)实验结果
从表2结果可以看出，化合物治疗组的鼠耳肿胀度与生理盐水组相比具有显著性差异，表明化合物在发挥体内抗血栓作用的剂量下，还具有抗炎作用。根据表1的数据演绎，其它化合物也有相应的技术效果。
表2 1nmol/kg化合物8a和8c的抗炎活性
n＝12；a)与生理盐水相比p<0.01；b)与生理盐水相比p<0.01,与阿司匹林比p>0.05。
Claims (4)
1.通式I的4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3,
式中AA1-AA2-Asp-AA3为Ala-Gly-Asp-Val。
2.权利要求1所述的通式I的4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3的制备方法，AA1-AA2-Asp-AA3为Ala-Gly-Asp-Val，该方法包括：
(1) L-组氨酸在稀硫酸催化下与甲醛进行Pictet-Spengler缩合生成4,5,6,7-四氢-3H-咪唑并吡啶-6-羧酸；
(2) 4,5,6,7-四氢-3H-咪唑并吡啶-6-羧酸转化为3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-羧酸；
(3) 3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-羧酸与Nα-Boc-Lys-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Nα-Boc-Lys-OBzl；
(4)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Nα-Boc-Lys-OBzl在2N NaOH溶液中皂化成3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Nα-Boc-Lys；
(5)Boc-Ala与甘氨酸苄酯偶联得到Boc-Ala-Gly-OBzl；
(6)Boc-Ala-Gly-OBzl在2N NaOH溶液中皂化成Boc-Ala-Gly；
(7)Boc-β-羧基-OBzl-Asp与缬氨酸苄酯偶联得到Boc-β-羧基-OBzl-Asp-Val-OBzl；
(8)Boc-β-羧基-OBzl-Asp-Val-OBzl在4N 氯化氢的乙酸乙酯溶液中得到L-β-羧基-OBzl-Asp-Val-OBzl；
(9)Boc-Ala-Gly与L-β-羧基-OBzl-Asp-Val-OBzl偶联得到Boc-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl；
(10)Boc-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl在4N氯化氢的乙酸乙酯溶液中得到L-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl；
(11)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Nα-Boc-Lys与L-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl偶联得到3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Boc-Lys -Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl；
(12)3,5-二-Boc-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Boc-Lys-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl在4N 氯化氢的乙酸乙酯溶液中得到4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl;
(13)4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl与Boc- -Lys(Z)偶联得到Nα-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Boc-Lys-(Z-Lys)-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl；
(14)Nα-4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Boc-Lys-(Z-Lys)-Ala-Gly-β-羧基-OBzl-Asp-Val-OBzl在三氟醋酸/三氟甲磺酸中得到4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰- Lys(Lys)-Ala-Gly-Asp-Val。
3.权利要求1所述的4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3在制备抗血栓药物中的应用。
4.权利要求1所述的4,5,6,7-四氢-3H-咪唑并吡啶-6-甲酰-Lys(Lys)-AA1-AA2-Asp-AA3在制备抗炎药物中的应用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510351700X | 2015-06-23 | ||
| CN201510351700 | 2015-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107698660A CN107698660A (zh) | 2018-02-16 |
| CN107698660B true CN107698660B (zh) | 2021-06-08 |
Family
ID=61168214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510642709.6A Expired - Fee Related CN107698660B (zh) | 2015-06-23 | 2015-10-02 | 咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107698660B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112010926B (zh) * | 2019-05-28 | 2022-04-22 | 首都医科大学 | Kgh及羟甲基修饰的苯并咪唑喹唑啉,其合成,活性和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101497651A (zh) * | 2008-01-30 | 2009-08-05 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN102164922A (zh) * | 2008-09-25 | 2011-08-24 | 贝林格尔.英格海姆国际有限公司 | 作为抗炎药的3h-咪唑并[4，5-c]吡啶-6-甲酰胺 |
| CN102796167A (zh) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-L-脯氨酰-L-丙氨酰-L-氨基酸及其制备方法和应用 |
| CN102807600A (zh) * | 2011-06-03 | 2012-12-05 | 首都医科大学 | 氨基酸修饰的菠菜素衍生物及其制备方法和应用 |
| CN103159835A (zh) * | 2011-12-13 | 2013-06-19 | 首都医科大学 | Lys及寡肽修饰的姜黄素衍生物、其合成及在医学中的应用 |
| CN103450196A (zh) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Agdv肽修饰的咔啉并六氢吡嗪-1，4-二酮、其制备方法、抗血栓作用和应用 |
-
2015
- 2015-10-02 CN CN201510642709.6A patent/CN107698660B/zh not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101497651A (zh) * | 2008-01-30 | 2009-08-05 | 首都医科大学 | 具有溶血栓活性的化合物、其制备方法、其应用 |
| CN102164922A (zh) * | 2008-09-25 | 2011-08-24 | 贝林格尔.英格海姆国际有限公司 | 作为抗炎药的3h-咪唑并[4，5-c]吡啶-6-甲酰胺 |
| CN102796167A (zh) * | 2011-05-26 | 2012-11-28 | 首都医科大学 | (S)-4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶-6-甲酰-L-脯氨酰-L-丙氨酰-L-氨基酸及其制备方法和应用 |
| CN102807600A (zh) * | 2011-06-03 | 2012-12-05 | 首都医科大学 | 氨基酸修饰的菠菜素衍生物及其制备方法和应用 |
| CN103159835A (zh) * | 2011-12-13 | 2013-06-19 | 首都医科大学 | Lys及寡肽修饰的姜黄素衍生物、其合成及在医学中的应用 |
| CN103450196A (zh) * | 2012-05-29 | 2013-12-18 | 首都医科大学 | Agdv肽修饰的咔啉并六氢吡嗪-1，4-二酮、其制备方法、抗血栓作用和应用 |
Non-Patent Citations (1)
| Title |
|---|
| 寡肽药物先导结构的发现与优化;赵明等;《北京大学学报（医学版）》;20021031;第34卷(第4期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107698660A (zh) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107686483B (zh) | 七环缩醛,其制备,抗栓活性和应用 | |
| AU2014277416B2 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
| CN104530199B (zh) | 一种抗肿瘤多肽及其制备方法和应用 | |
| CN107698660B (zh) | 咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用 | |
| JP3149199B2 (ja) | アンジオテンシン変換酵素阻害ペプチド | |
| CN109912693A (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
| WO2016062234A1 (zh) | 八肽修饰的地塞米松,其制备,纳米结构和应用 | |
| CN109912692A (zh) | Yigsk修饰的七环醛, 其制备，抗栓活性和应用 | |
| CN106349332B (zh) | 咪唑并吡啶酰-krgdv，其合成，抗血栓活性和应用 | |
| CN110577583B (zh) | Rgdf修饰的七环醛,其合成,抗栓活性和应用 | |
| CN110563799B (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
| CN101265292B (zh) | 多肽类物质、其制备方法及其用途 | |
| JPH0614794A (ja) | 大豆蛋白質起源のペプチドからなる免疫系賦活組成物 | |
| CN107459557B (zh) | 左旋维c-2-氧乙酰-grpak,其合成,活性和应用 | |
| CN110577571B (zh) | Yigsk修饰的七环醛,其合成,抗栓活性和应用 | |
| CN110577575B (zh) | 1S-甲基-β-四氢咔啉酰-K(ARPAK)-RGDV,其合成,活性和应用 | |
| CN110577569B (zh) | Rgdv修饰的七环醛,其合成,抗栓活性和应用 | |
| CN110577582B (zh) | Ldv修饰的七环醛,其合成,抗栓活性和应用 | |
| CN106432416B (zh) | 五甲氧色胺基羰丙酰-rgdv,其制备,活性和应用 | |
| CN104086626B (zh) | 一种固相多肽合成抗炎十肽的制备方法 | |
| CN102477078B (zh) | 胸腺体液因子(THF)-γ2改构肽的制备及其药物组合物的用途 | |
| CN107033215A (zh) | 咪唑并吡啶酰-kagdv，其合成，抗血栓活性和应用 | |
| CN110577584A (zh) | 1S-甲基-β-四氢咔啉酰-K(RPAK)-RGDV,其合成,活性和应用 | |
| CN107459556A (zh) | 左旋维c-2-氧乙酰-pakpak,其合成,活性和应用 | |
| JP2003128695A (ja) | 新規なトリペプチドおよびアンジオテンシン変換酵素阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210608 |